7EY Stock Chart & Stats
€0.38
€0.00(0.00%)
At close: 4:00 PM EDT
€0.38
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.38 - €0.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.59M
Enterprise Value-€0.26
Total Cash (Recent Filing)€16.84M
Total Debt (Recent Filing)€333.02K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.30Price Target Upside2610.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.33
Revenue Forecast (FY)€1.32M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt limits interest and refinancing pressure, preserving financial flexibility while Kiora funds research. This is especially valuable for a development-stage biotech without recurring commercial revenue, although continued losses could still reduce its equity base.
KIO-301 LicensingThe South Korean partnership creates non-dilutive near-term funding potential and an additional commercialization route for KIO-301. Broader regional coverage can reduce Kiora’s direct development burden while retaining milestone and royalty participation.
Platform ExpansionEvidence of activity beyond retinal disease expands the potential addressable indications for Kiora’s ion-channel platform. If confirmed in further studies, neurological applications could diversify the pipeline and improve strategic partnering opportunities.
Bears Say
No Current RevenueThe absence of recurring revenue leaves Kiora dependent on financing, partnerships or successful clinical development to fund operations. The reversal from $16.0M revenue and $3.6M profit in 2024 also shows limited revenue consistency and high earnings risk.
Sustained Cash BurnPersistent negative operating and free cash flow indicates that core activities consume capital rather than generate it. Without commercial products or positive cash generation, Kiora may need additional funding, potentially limiting development pace or increasing dilution.
Potential Equity DilutionThe expanded equity plan can help attract and retain specialized biotech talent, but future share issuance may dilute existing holders. Combined with ongoing cash burn, reliance on equity-based funding could increase the long-term cost of financing operations.
Kiora Pharmaceuticals News
7EY FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was €0.38 and its highest was €0.46 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is €9.59M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Nov 06, 2026 which is in 64 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Aug 07, 2026. The company reported -€0.295 earnings per share for the quarter, beating the consensus estimate of -€0.408 by €0.113.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.33.
How many shares outstanding does Kiora Pharmaceuticals have?
Currently, no data Available
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -€0.295 in its last earnings report, beating expectations of -€0.408. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:7EY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
7EY Stock 12 Month Forecast
Average Price Target
€10.30
▲(2610.61% Upside)